Future Prospects of Global Laboratory Proficiency Testing Market

An Overview of the Global Theranostics Market
Theranostics is a relatively young
branch of medicine that uses targeted medicines to perform specific targeted
testing. These tests are mostly used to diagnose malignancies of various types.
Patient-centered treatment with a more tailored and accurate approach is a
major concern in medicines. The method combines diagnostic and therapeutic
applications to create a single agent. End-users gain from the system because
it improves drug delivery, diagnostics, and treatment response monitoring.
Theranostics market is predicted to increase significantly in the near future
due to rising cancer occurrences and the growing need for cancer combination
medicines.
Global Theranostics Market Drivers
Theranostics
market growth is likely to be boosted
by the development of novel companion diagnostic tests to be utilised with
existing treatment options over the forecast period. Leading manufacturers are
working to bring new companion diagnostic tests to the market. In 2017,
Illumina, Inc. announced the launch of a U.S. Food and Drug Administration
(FDA) approved extended RAS panel for identifying patients eligible for
Vectibix (panitumumab) treatment of metastatic colorectal cancer.
Theranostics Market |
Over the forecast period, increasing
laboratory usage of companion diagnostic tests is expected to fuel global
theranostics market growth. In July 2018, the Diagnostic Laboratories of the
BloodCenter of Wisconsin began offering the Abbott RealTime IDH1 assay for
patients with acute myeloid leukaemia (AML).
Market Dynamics in the Global Theranostics
Industry
The worldwide theranostics industry is
being driven by the rising incidence of cardiovascular and cancer diseases.
According to the World Health Organization, 17.9 million people died from
cardiovascular illnesses in 2016. Furthermore, ongoing research initiatives in
these domains contribute significantly to market growth. Furthermore, the
growing number of strategic alliances and partnerships is expected to move the
overall industry forward at a rapid rate. Biocartis Group NV and Amgen Inc.
teamed in 2018 to develop companion diagnostic tests for Veectibix, an Amgen
medication.
Comments
Post a Comment